ENPP1 is a membrane-associated enzyme in the extracellular nucleotide-metabolism network that can degrade tumor-derived 2′,3′-cGAMP and promote adenosine production through the AMP–CD73 pathway. Targeting ENPP1 protects extracellular cGAMP and restores its ability to activate the STING pathway in host immune cells.

Keywords: ENPP1; cGAS; STING; 2′,3′-cGAMP; TBK1; IRF3; CD73; adenosine; tumor immunity

1 Overview of ENPP1 as a Target

1.1 Molecular Identity and Localization

Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), also known as PC-1 or CD203a, is a member of the ENPP family. ENPP1 is a type II transmembrane glycoprotein. Its short N-terminal cytoplasmic region and single transmembrane segment anchor the protein to the plasma membrane, whereas its principal catalytic region is extracellular and can directly access extracellular nucleotide substrates such as ATP and 2′,3′-cGAMP.

1.2 Forms of ENPP1

ENPP1 can be expressed on the surfaces of tumor cells, fibroblasts, certain immune cells, osteoblasts, and chondrocytes and may also be present in soluble fractions or extracellular vesicles. ENPP1 carried by tumor-derived extracellular vesicles retains the ability to degrade extracellular cGAMP, extending its activity beyond the surface of ENPP1-expressing cells. Evaluation of ENPP1 in the tumor microenvironment should therefore consider contributions from tumor cells, stromal cells, immune cells, and extracellular vesicles.

1.3 Physiological Substrates and Major Functions

ENPP1 has a broad nucleotide substrate spectrum, among which ATP and 2′,3′-cGAMP correspond to two important biological functions. ENPP1 hydrolyzes ATP to generate AMP and pyrophosphate (PPi), participating in extracellular purine metabolism and tissue-mineralization control. Hydrolysis of 2′,3′-cGAMP restricts extracellular cGAMP–STING signaling. Loss of ENPP1 function can cause PPi deficiency and abnormal calcification, indicating that mineralization-related safety must be evaluated during systemic ENPP1 inhibition.

1.4 Protein Expression Is Not Equivalent to Catalytic Activity

Increased ENPP1 protein expression does not necessarily indicate a corresponding increase in extracellular cGAMP hydrolysis. Actual enzymatic activity is influenced by cell-surface localization, integrity of the catalytic structure, the local Zn²⁺ environment, substrate concentration, and extracellular-vesicle release. ENPP1 expression is suitable for preliminary stratification, whereas the cGAMP hydrolysis rate, AMP/GMP production, and extracellular cGAMP half-life are more representative functional biomarkers.

2 ENPP1 Controls Extracellular cGAMP–STING Signaling

2.1 cGAS Produces 2′,3′-cGAMP

Chromosome missegregation, DNA damage, and micronuclear-envelope rupture can expose genomic DNA to the cytoplasm. After recognizing cytoplasmic double-stranded DNA, cyclic GMP-AMP synthase (cGAS) uses ATP and GTP as substrates to synthesize 2′,3′-cyclic guanosine monophosphate–adenosine monophosphate (2′,3′-cGAMP). Intracellular cGAMP binds the stimulator of interferon genes (STING) on the endoplasmic reticulum, promoting STING trafficking to the Golgi apparatus and activation of TBK1–IRF3 signaling.

2.2 cGAMP Functions as an Intercellular Immune Messenger

cGAMP produced by tumor cells can enter the extracellular space through membrane channels, transporters, or extracellular vesicles and subsequently be taken up by host cells such as dendritic cells, monocytes, and macrophages. The SLC46A2 transporter and LRRC8A:C/E heteromeric volume-regulated anion channels participate in cGAMP transmembrane transport in different cellular contexts, allowing tumor-derived cGAMP to induce TBK1 and IRF3 phosphorylation in host immune cells and promote type I interferon, chemokine, and antigen-presentation programs.

2.3 ENPP1 Defines the Signaling Window of cGAMP

Extracellular cGAMP has a limited signaling window between its release and uptake by immune cells. ENPP1 acts within this window and can degrade cGAMP before it reaches recipient cells. Increased ENPP1 activity shortens the cGAMP half-life and limits its effective signaling distance, whereas ENPP1 inhibition increases local cGAMP concentrations and prolongs paracrine signaling between tumor cells and immune cells.

3 Structure and Catalytic Mechanism of ENPP1

3.1 Domain Organization

The extracellular region of ENPP1 comprises two somatomedin B-like domains, a phosphodiesterase catalytic domain, and a nuclease-like domain. The catalytic domain mediates nucleotide recognition and phosphodiester-bond hydrolysis, whereas the nuclease-like domain primarily contributes to conformational stability. The spatial relationship between the catalytic and nuclease-like domains is important for enzymatic activity. The somatomedin B-like domains are not required for cGAMP hydrolysis but may influence protein localization, molecular interactions, and behavior at the membrane surface.

3.2 Dinuclear Metal Catalytic Center

The ENPP1 catalytic center contains two Zn²⁺ ions coordinated by multiple aspartate, histidine, and threonine residues. Together, the two Zn²⁺ ions stabilize the substrate phosphate groups and facilitate nucleophilic attack, leading to phosphodiester-bond cleavage. A Ca²⁺-binding region within the nuclease-like domain helps maintain conformational stability between the catalytic and nuclease-like domains but does not directly catalyze hydrolysis of the cGAMP phosphodiester bonds.

3.3 Sequential Hydrolysis of 2′,3′-cGAMP

2′,3′-cGAMP contains both 2′–5′ and 3′–5′ phosphodiester bonds. ENPP1 binds cGAMP through its nucleoside-recognition pocket and metal catalytic center, initially hydrolyzing one phosphodiester bond to generate the linear intermediate pApG. After pApG is repositioned, the second phosphodiester bond is hydrolyzed, ultimately generating 5′-AMP and 5′-GMP. Disruption of the cyclic scaffold eliminates the structural basis required for STING activation.

3.4 ATP Hydrolysis and PPi Production

ENPP1 hydrolyzes ATP to generate AMP and PPi. AMP can enter the CD73–adenosine metabolic branch, whereas PPi inhibits hydroxyapatite deposition and participates in the balance of bone and soft-tissue mineralization. Candidate ENPP1 inhibitors should be evaluated separately for their effects on cGAMP and ATP hydrolysis. Selectivity cannot be determined solely from a single artificial substrate or total phosphodiesterase activity.

4 Mechanistic Basis for Targeting ENPP1

4.1 Releasing an Extracellular Innate Immune Checkpoint

ENPP1 is positioned between cGAMP-producing cells and STING-responsive cells, where its catalytic activity can prevent tumor-derived cGAMP from reaching host immune cells. ENPP1 inhibition does not actively synthesize cGAMP but protects endogenous cGAMP that has already been produced and released by tumor cells, allowing DNA-damage signals to re-enter the STING pathway in dendritic cells, monocytes, and macrophages.

4.2 Concurrent Regulation of the STING and Adenosine Branches

ENPP1-mediated degradation of cGAMP generates AMP, which can be converted into adenosine by the extracellular 5′-nucleotidase CD73. Adenosine binds A2A receptors on immune cells and increases intracellular cAMP, suppressing T-cell activation, cytotoxic mediator release, and antigen-presenting cell function. ENPP1 therefore simultaneously reduces immunostimulatory cGAMP and generates AMP for adenosine production, forming a metabolic node that connects STING suppression with adenosine-mediated immunosuppression.

4.3 Exploiting STING in Host Immune Cells

ENPP1 may remain a viable target even when STING expression is reduced in tumor cells. Provided that tumor cells retain cGAS activity and can produce and release cGAMP, extracellular cGAMP can still act on host immune cells with an intact STING pathway. The potential value of ENPP1 targeting should therefore be evaluated jointly according to tumor cGAS activity, extracellular cGAMP, ENPP1 catalytic activity, and STING function in host immune cells.

4.4 Distinction from Direct STING Agonism

4.5 Molecular Stratification for ENPP1 Targeting

High ENPP1 expression alone is insufficient to predict drug sensitivity. A more appropriate stratification strategy should include the cGAMP source, ENPP1 catalytic state, STING function in recipient cells, and the CD73–adenosine branch. When cGAS expression is low, cGAMP export is insufficient, or STING is inactive in host immune cells, ENPP1 inhibition may fail to generate an effective immune output even if ENPP1 expression is high.

4.6 Mechanistic Basis for Combination Therapy

(1) DNA-Damaging Therapy

Radiotherapy and certain DNA-damaging agents can increase cytoplasmic DNA exposure and micronucleus formation, providing substrates for cGAS. ENPP1 inhibition can reduce extracellular degradation of newly generated cGAMP, allowing DNA damage to be converted more effectively into STING signaling in host immune cells.

(2) PARP Inhibition

Tumors with homologous recombination repair defects can accumulate DNA damage and exhibit increased cGAS activation following PARP inhibition. This combination requires confirmation that the tumor actually produces and exports cGAMP. Increased DNA-damage markers alone are insufficient to determine whether ENPP1 inhibition will be effective.

(3) Immune Checkpoint Blockade

ENPP1 inhibition primarily enhances innate immune initiation, antigen presentation, and immune-cell recruitment, whereas PD-1/PD-L1 blockade mainly relieves suppression of effector T cells. The two interventions act at the initiation and effector stages of the immune response, respectively, and may provide complementary effects.

(4) CD73 or A2A Receptor Blockade

When the ENPP1–AMP–CD73–adenosine branch is highly active, ENPP1 inhibition can be combined with CD73 inhibition or A2A receptor intervention. Extracellular cGAMP, AMP, and adenosine should be measured concurrently to distinguish the contribution of STING restoration from relief of adenosine-mediated suppression.

5 Experimental Evaluation of the ENPP1–STING Mechanism

5.1 Evaluation of ENPP1 Expression and Activity

ENPP1 expression can be assessed by RT-qPCR, immunoblotting, flow cytometry, or immunohistochemistry. Flow cytometry and cell-surface staining under nonpermeabilizing conditions are more suitable for evaluating membrane localization. Functional assessment should further measure the ability of cell or tissue samples to hydrolyze 2′,3′-cGAMP, avoiding inference of extracellular catalytic activity solely from total protein expression.

5.2 Direct Enzymatic Evaluation

An in vitro hydrolysis system can be established using recombinant ENPP1 and 2′,3′-cGAMP. LC–MS, HPLC, or product-detection methods can be used to analyze cGAMP depletion and AMP/GMP production and to determine inhibitory activity, time dependence, and reversibility within the initial reaction-rate range. ATP can serve as an orthogonal substrate for evaluating substrate selectivity, whereas ENPP3, CD39, CD73, and other metal-dependent enzymes can be used to exclude nonspecific inhibition and metal-chelating effects.

5.3 Donor–Recipient Cell Models

Tumor cells with functional cGAS can serve as cGAMP donors, whereas dendritic cells, monocytes, or macrophages with intact STING function can serve as recipient cells. After collecting donor-cell-conditioned medium, cGAMP, AMP, and adenosine can be measured, followed by assessment of p-TBK1, p-IRF3, IFN-β, and CXCL10 in recipient cells. Exogenous cGAMP is suitable for evaluating ENPP1 hydrolysis and recipient-cell uptake, whereas endogenous cGAMP models validate the complete tumor cell–immune cell paracrine pathway.

5.4 Evaluation of In Vivo Pharmacodynamics and Safety

In vivo studies should preferentially use immunocompetent syngeneic transplantation models with responsive cGAS–STING pathways and should distinguish between tumor-cell ENPP1 and host ENPP1. Pharmacodynamic indicators can include stromal cGAMP, p-TBK1 and p-IRF3 in immune cells, type I interferon signatures, dendritic-cell maturation, CD8⁺ T-cell infiltration, and metastatic burden. Safety assessment should cover serum and tissue PPi, soft-tissue calcification, bone mineralization, inflammatory cytokines, and pathological changes in major organs.

6 Products Related to the ENPP1–STING Pathway

6.1 Products for Studying ENPP1 and Its Substrates

6.2 Products for Studying the cGAS–STING–TBK1–IRF3 Pathway

6.3 Products for Studying the CD73–Adenosine Branch and Functional Outputs

ENPP1 is a key extracellular enzyme connecting extracellular cGAMP degradation, STING suppression, and adenosine production. Its value as a therapeutic target should be assessed jointly according to the tumor-derived cGAMP source, actual ENPP1 catalytic activity, and the responsiveness of the STING pathway in host immune cells.

References

[1] Wang S, Böhnert V, Joseph AJ, et al. ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer. Proc Natl Acad Sci U S A. 2023;120(52):e2313693120. doi:10.1073/pnas.2313693120.

[2] Li L, Yin Q, Kuss P, et al. Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat Chem Biol. 2014;10(12):1043-1048. doi:10.1038/nchembio.1661.

[3] Kato K, Nishimasu H, Oikawa D, et al. Structural insights into cGAMP degradation by ecto-nucleotide pyrophosphatase phosphodiesterase 1. Nat Commun. 2018;9:4424. doi:10.1038/s41467-018-06922-7.

[4] Carozza JA, Böhnert V, Nguyen KC, et al. Extracellular cGAMP is a cancer cell-produced immunotransmitter involved in radiation-induced anti-cancer immunity. Nat Cancer. 2020;1(2):184-196. doi:10.1038/s43018-020-0028-4.

[5] Carozza JA, Brown JA, Böhnert V, et al. Structure-Aided Development of Small-Molecule Inhibitors of ENPP1, the Extracellular Phosphodiesterase of the Immunotransmitter cGAMP. Cell Chem Biol. 2020;27(11):1347-1358.e5. doi:10.1016/j.chembiol.2020.07.007.

For more related articles, please see below:

[1] mtDNA Stress and cGAS–STING/AIM2 Innate Immune Activation Mediated by CRAT Deficiency